“Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s96. doi:10.25251/skin.4.supp.96.